Patent EP0139286A2 successfully refreshed from Google Patents.
EP0139286A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Prolonged sustained-release preparations
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1984-10-12
•
Granted: —
•
Expires: 2004-10-12
Abstract
Abstract A sustained-release preparation in the form of a needle-like or bar-like shape, which comprises an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, polysaccharides and synthetic high molecular compounds, preferably collagen, atelocollagen, gelatin, and a mixture thereof). The sustained-release preparation can be administered to the body or implanted into the body by injection or injection-like methods and can release the active ingredient at an effective level for a long period of time when administered.
Inventors
- 👤 Yoshiya Yamahira
- 👤 Keiji Fujioka
- 👤 Shigeji Sato
- 👤 Noboru Yoshida
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 17:14
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K31/41; A61K31/415; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/212; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2063
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
23 words
A sustained-release injection, which comprises an active ingredient and a pharmaceutically acceptable biodegradable carrier in the form of a needle-like or bar-like shape.
Claim 2
Dependent Claim
23 words
A sustained-release injection, which comprises an active ingredient and a pharmaceutically acceptable biodegradable carrier in the form of a needle-like or bar-like shape.
Claim 3
Dependent Claim
26 words
The preparation according to claim 1, wherein the biodegradable carrier is a member selected from the group consisting of proteins, polysaccharides and synthetic high molecular compounds.
Claim 4
Dependent Claim
26 words
The preparation according to claim 1, wherein the biodegradable carrier is a member selected from the group consisting of collagen, atelocollagen, gelatin, and a mixture thereof.
Claim 5
Dependent Claim
40 words
The preparation according to claim 1, wherein active ingredient is a member selected from the group consisting of indomethacin, prostaglandins, prostacyclines, - bio-hormones, adriamycin, bleomycins, tespamin, mitomycin, interferon, interleukin, tumor necrosis factor, and 4-carbamoyl-imidazolium-5-oleate or a salt or hydrate thereof.
Claim 6
Dependent Claim
25 words
The preparation according to claim 1, wherein the active ingredient is a member selected from the group consisting of interferon, interleukin and tumor necrosis factor.
Claim 7
Independent Claim
43 words
A method for the preparation of a sustained-release preparation, which comprises mixing an active ingredient and a pharmaceutically acceptable biodegradable carrier to incorporate the active ingredient in a carrier matrix, pulverizing the carrier matrix, and then forming into a needle-like or bar-like shape.
Claim 8
Independent Claim
43 words
A method for the preparation of a sustained-release preparation, which comprises mixing an active ingredient and a pharmaceutically acceptable biodegradable carrier to incorporate the active ingredient in a carrier matrix, pulverizing the carrier matrix, and then forming into a needle-like or bar-like shape.
Claim 9
Dependent Claim
37 words
A device for administering a sustained-release preparation in the form of a needle-like or bar-like shape as set forth in claim 1, which comprises an injection needle and a pushing pole which freely slides within the needle.
Claim 10
Dependent Claim
40 words
A device for administering a sustained-release preparation in the form of a needle-like or bar-like shape as set forth in claim 1, which comprises (i) a fine tube and (ii) an internal needle which freely slides within the fine tube.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.